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2Abstract
Physiological functions of the two extreme ends of the age spectrum, children (< 18 years old) and
older adults (aged 65 years and over), differ from healthy young adults. This consequently affects
the pharmacokinetic profiles of administered drugs, which, in turn, impacts upon clinical practice
and drug therapy. The gastrointestinal milieu acts as a distinct and vital organ regulating the
dissolution, absorption and metabolism of orally ingested drugs. Age-mediated alteration in the
physiology and function of the gut can reshape the pharmacokinetics of certain drugs. However, our
understanding of this topic is limited. This article references the gut physiology of healthy adults to
capture the available evidence in the literature on the extent and nature of the changes in childhood
and older age. The gut, as an organ, is examined with regards to the effect of age on luminal fluid,
microbiota, transit and motility, and the intestinal mucosa. Whilst drastic developmental changes
were observed in certain aspects of the gastrointestinal environment, the examination reveals
significant gaps in our knowledge in the physiology and function of the developing or ageing gut.
The revelation of the unknown paves the way towards a better characterization of the human
gastrointestinal tract for optimized drug therapy in children and older adults.
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31. Introduction
The duration of the human life cycle and the age of the individual at death are both circumstances
dependent on multiple interdisciplinary factors, ranging from living environment to nutrition,
healthcare resource availability and the adoption of so-called ‘lifestyle’ changes such as heavy
alcohol consumption, recreational drug use and cigarette smoking. The life expectancy of an
individual also varies from one geographical location to another; good individual quality of life,
therefore, may be reflective of a greater proportion of the population entering the elderly phase of
life through undertaking of collective practices perceived as beneficial to prolongation of life (for
instance, dietary, based on communal food production or availability). It has been estimated that the
majority of babies born since the year 2000 in developed nations such as the United Kingdom, USA
and Canada will be much more likely, for instance, to reach their 100th birthdays if the current
observed increase in life expectancy for members of these populations is continued (Christensen et
al., 2009). At present, the demographic most affected by this increase is by and large comprised of
individuals aged 85 years and older (Wade, 2002) – to this end, it is also thought that around 18% of
the US population will be accounted for by those over the age of 70 by the year 2025 (Elsner, 2002).
The natural human growing process is the cumulative effect of growth and development of different
bodily organs, including the gastrointestinal tract. The gut, as with other organs, evolves and
develops during gestation from a basic structure – in this case, analogous to a simple hollow tube –
into a more functionalized and complex cellular system. Soon after labour, maternal support to the
foetus ends, and the newborn subsequently encounters various bio-physiological challenges, such as
breathing and feeding independently. Thus begins a crucial period for the functional maturity of the
gut and its luminal environment with changes in digestive and transport function taking place under
the influence of genetic and neurohormonal regulators that mediate gut development (Collins et al.,
2006). Babies which are breastfed and those who are formula-fed harbor different bacterial species
in their gut, though such differences are normally shown to dissipate after weaning at around two
4years of age. This dynamic behaviour distinguishes the gut as a unique organ, whereby intra-organ –
more precisely, intra-luminal – conditions are seen to be highly variable. Such variability is otherwise
thought to be a consequence of the complex interplay between various factors ranging from feeding
behaviour to genetics influences; gender; disease; and, somewhat inevitably, ageing.
Humans enter into adulthood as the body reaches maturity and this is followed by a downturn in
advanced age. As we age, the gastrointestinal tract undergoes various morphological and functional
changes, paralleling a general decline in bodily function. This involves circumstances such as delayed
gastric emptying, reduced splanchnic blood flow and changes in gastrointestinal pH (Wilkinson,
1997). Such age-related changes disturb normal homeostatic mechanisms, however, and so
predispose the gut to the development of certain diseases (Majumdar and Basson, 2006; Newton,
2004).
The intra-luminal environment directly influences drug bioavailability, and hence the performance of
orally-administered formulations (Bai et al., 2015). The same is also true of intravenously-delivered
drugs, whereby drug molecules may encounter the gut environment following hepatic diffusion or
secretory processes (Arimori and Nakano, 1998). The anatomical and physiological changes, due to
the development of children and the declination in advanced age alike, significantly impact upon the
pharmacokinetics of certain drugs (Gidal, 2006; Roy and Varsha, 2005; Smits and Lefebvre, 1996). An
understanding of the gastrointestinal environment for members of different age groups is therefore
vital for the successful delivery of drugs to achieve required therapeutic outcomes in these target
patient categories – broadly, the young, adult and elderly. The primary objective of this paper is to
provide a general overview of the developmental changes observed in certain aspects of the
gastrointestinal environment with respect to age, with particular emphasis on the lumen,
microbiota, mucosa, and intestinal transit and motility. A secondary aim of this paper is to highlight
the knowledge gaps in the physiology and function of the developing or ageing gut.
52. Changes in the physiology and function of the developing and ageing gut
The effects of ageing (young and elderly) on the physiology and function of the gastrointestinal tract
have been investigated using various models leading to reports suggesting changes in circumstances
such as gastric pH, gastrointestinal motility, serum albumin, hepatic and renal function, lean body
mass and body fat when compared to younger adults influence pharmacokinetic parameters (Gidal,
2006; Roy and Varsha, 2005; Smits and Lefebvre, 1996). With age, an alteration in drug-
metabolizing enzyme activity is also reported, causing a change in oral bioavailability and the plasma
concentrations of drugs susceptible to first-pass metabolism (Wilkinson, 1997). However,
information on age-mediated changes in gastrointestinal milieu is scarce, and there remain gaps in
our knowledge. Batchelor et al., (2014) have reviewed physiological and pharmaceutical factors
manipulating solubility and permeability in the paediatric population and reemphasised the current
lack of appreciation of age-mediated differences in gastrointestinal tract postpartum. Moreover,
age-related physiological changes in the gut have been reported to be variable mainly due to the
cellular and molecular changes in the system (Saffrey, 2014). To this end, the literature presently
available on human modeling has been summarized and discussed in Table 1 below.
2.1 Changes in gastrointestinal fluid
2.1.1. Fluid volumes
Extensive studies investigating gastrointestinal water effects in humans are considerably lacking,
though one publication of relevance is that by Gotch et al (1957), who measured the gastrointestinal
water in thirteen human subjects (8 male and 5 female) post-mortem. Interestingly, the data
represents elderly subjects aged 50 years and over (63 ± 9 years), with gut contents only measured
up to the transverse colon. In another study, colonic mass was measured in forty six subjects (18
female, 28 male) of lower ages (48 ± 3 years) (Cummings, 1990), and Schiller et al (2005) measured
the intestinal fluid volumes in even younger subjects (23-45 years). More recently, Mudie et al
(2014) and Koziolek et al (2014) reported the fasted-state gastric fluid volume in young adults
6comparable to Schiller et al (2005). However, it is to be noted that the measurements in older
studies (Cummings, 1990; Gotch et al., 1957) were post-mortem and determined gravimetrically,
whereas newer studies (Koziolek et al., 2014; Mudie et al., 2014; Schiller et al., 2005) refer to the
‘free water’ estimated in-vivo using magnetic resonance imaging. The data does not, therefore,
include water bound to the gastrointestinal mass in the lumen, and so the data from older and
newer studies may not be directly comparable. It is, however, noticed across different studies that
gastrointestinal water varies significantly between subjects, and this inter-subject variability should
be considered while planning further studies in comparing gastrointestinal fluid volumes on ageing.
Given that we know the body weight and size of the gastrointestinal tract to increase significantly
from youth (childhood) to adulthood (puberty), it would be reasonable to assume that
gastrointestinal mass also increases in humans from childhood to puberty (though there is no direct
evidence in the literature to support this). The size and type of meal also influence the development
of the gastrointestinal tract, whereas individual food choices may also adjust with age (Drewnowski
and Shultz, 2001), with implications for gastrointestinal mass and luminal water content in subjects
of different age groups.
2.1.2 pH
The gastric pH in neonates is neutral and drops to acidic values over the first two years of life
(Bowles et al., 2010), with average gastric pH in 248 children after a 6-8 hours fast was reported as
1.37 ± 1.6, where 87 % of the children had a gastric pH of < 2.5 (Schwartz et al., 1998).
It is worth mentioning that children from 2 months to 18 years of age were included in this study
and therefore average pH values may mask potential trends in gastric pH of infants (<1 mo), toddlers
(<2 y), children (2-11 y) and adolescents (12-18 y). This pH data is, however, in agreement with ten
different studies compiled by the authors who measured gastric pH of children (without GI
symptoms who were fasted for a comparable time) in the range of 1.7 to 2.1 (Schwartz et al., 1998).
The pH of 12 healthy children (5 boys and 7 girls, aged 8-14 years, median 12 y) measured after an 8-
hours fast by a radio-telemetry capsule (where upon subjects continued to fast until gastric
7emptying) was also comparable to that observed in adults as part of a different study from the same
researchers using the pH capsule (Fallingborg et al., 1989; Fallingborg et al., 1990).
The pH in the elderly human stomach was also found to be very acidic (Hurwitz et al., 1997), though
evidence was lacking to suggest that these values were different for the adult or child human.
Feldman previously reviewed available evidence on gastric pH in the elderly, and suggested that the
stomach of elderly subjects retains the capacity to secrete markedly high levels of gastric acid; a
characteristic which does not appear to diminish with age (Feldman, 1997). Gastric and duodenal pH
in 79 healthy elderly subjects (Age, 71 ± 5 years) under fasting conditions was 1.3 (range, 1.1-1.6)
and 6.5 (range, 6.2-6.7), respectively. The gastric pH under fed conditions (1000 kcal meal) was
increased to 4.9 (range, 3.9-5.5), but duodenal pH was unaffected (6.5, range 5.4-6.7). Notably, the
rate of return of postprandially-raised gastric pH to acidic pH was comparatively slower in elderly
than in young subjects (Figure 1). In turn, different behaviours in gastric pH were observed in the
elderly subjects: the first being the typical behaviour of low fasting pH which was postprandially
increased and followed by a spontaneous decrease. Around 11% of subjects were found to be
achlorhydric (pH > 5 in fasted stomach), and in 45 % of these subjects, the median pH remained
higher than 5.0 postprandially (Russell et al., 1993). However, in spite of the rate of gastric acid
secretion being similar in older and younger individuals, the incidence of achlorhydria (characterized
by consistent acid hyposecretion) is approximately 10-20 % among elderly patients compared to only
<1 % in younger subjects (Gidal, 2007). It is estimated that in the USA alone, approximately 22 % of
the population suffer from hypochlorhydria (characterized by intermittent acid secretion) and
achlordydria; potentially compromising the oral bioavailability of certain drugs including Vitamin B12
(Russell, 1997). Elevated gastric pH was also shown to result in the compromised absorption of the
weakly basic drug dipyridamole in elderly achlorhydric subjects (Russell et al., 1994).
The information about the distal gut pH in the elderly is scarce; a number of studies have suggested
faecal pH in elderly human subjects was within the range of 6.57±0.10 (Bouhnik et al., 2007) and
86.97±0.75 (Chung et al., 2007), which is not too dissimilar from those values identified in adults and
children (Fallingborg et al., 1989; Fallingborg et al., 1990).
92.1.3 Buffer capacity
Information on the buffer capacity of the healthy human gastrointestinal fluids due to ageing is
equally scarce. The buffer capacity of gastric aspirates obtained from human volunteers (aged 20-32
years) was 14 mmol/L/ΔpH 30 minutes post-ingestion of a liquid meal (Ensure® Plus), which then 
increased to 28 mmol/L/ΔpH 210 minutes postprandially (Kalantzi et al., 2006). This was also related 
to the buffer capacity of the administered liquid meal itself (Ensure® Plus, 24 mmol/L/ΔpH). The 
buffer capacity of the duodenal aspirates varied between 18 and 30 mmol/L/ΔpH during 30 to 210 
minutes post meal ingestion (Kalantzi et al., 2006). However, it should be borne in mind that Kalantzi
and colleagues measured buffer capacity in whole gastric and duodenal aspirates; whereas the type
and calorific value of the food ingested during these experiments is thought to be crucial. Little is
known about the buffer capacity in the distal small intestine, however there is a report by Fadda et
al (2010), where buffer capacity of human jejunal and ileal fluids were reported as 3.2 and 6.4
mM/L/∆pH respectively, where jejunal fluids were aspirated from healthy volunteers and ileal fluids 
were obtained from patients undergoing surgery. The buffer capacity of the supernatants from
ascending colon fluids from  healthy human volunteers (aged 20-32 years) was ~18.9 mmol/L/ΔpH 
(Diakidou et al., 2009). However, a much higher buffer capacity (almost double) was estimated (37
mmol/L/ΔpH) when whole ascending colon fluids from humans were tested in place of the 
supernatants. The authors suggest that this is due to the consumption of titrated acid by the
bacteria-mediated reactions prevalent in the whole colonic fluids (Diakidou et al., 2009).
2.1.4 Bile salts
Bile acids (bile salts) are the major organic components of the bile secretion, accounting for 50% of
its solid content. Bile acids are released from the gall bladder into the duodenum after a meal. The
average values of the total bile acid concentration are similar in the duodenum and the jenunum but
decrease rapidly in the ileum due to reabsorption into the enterohepatic circulation (Dressman et
al., 1998).
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The mean values for the total duodenal bile acids concentration in the fasted state lie between 1.6-
5.9 mM (Armand et al., 1996; Clarysse et al., 2009; de la Cruz Moreno et al., 2006; Deferme et al.,
2003; Dressman et al., 1998; Lindahl et al., 1997; Persson et al., 2005). Postprandial luminal
concentration of bile acids reaches a maximum within 30 minutes and gradually declines afterwards
(Armand et al., 1996; Dressman et al., 1998; Fausa, 1974). The reported average bile acid
concentrations were around 10 mM within 60 minutes after meal ingestion (Armand et al., 1996;
Clarysse et al., 2009; Dressman et al., 1998; Fausa, 1974; Kalantzi et al., 2006; Persson et al., 2005).
However, high intra- and inter-individual variability in total bile acid concentrations were reported in
the literature, in both fasted and fed states. Clarysse et al., (2009) reported a time-dependent bile
acid concentration variation within individual subjects in the fasted state ranging from 0.3 to 9.6
mM. The total bile salt concentration varied from 0.5 to 5.5 mM inter-individually in the fasted state
in a study conducted by Moreno et al. (2006). High variability was also reported on postprandial bile
salt concentrations, ranging from 0.5 to 37 mM (Hernell et al., 1990; Ladas et al., 1984).
In the early life of foetuses, the primary bile acids, cholic and chenodeoxycholic acids, are secreted
by the liver, concentrated in the gallbladder and released into the fetal intestine (Watkins and
Perman, 1977). However, the pool size and the concentration of bile acids in the gallbladder of new
born infants (both pre-mature and full-term) was much lower than in older children and adults
(Bongiovanni, 1965; Watkins et al., 1975), which might contribute to lower neonate duodenal bile
acid concentrations. Challacombe et al., (1975) measured duodenal bile acid concentrations in three
age groups of infants 2 hours after a 5% dextrose feed. The duodenal bile acids was significantly
lower in infants under 2 days of age (1.65 ± 1.1 mM) and aged 2-7 days (3.33 ± 3.0 mM), compared
to infants aged 10 days to 7 months (8.47 ± mM) which is similar to the value reported in adults.
Low birth weight infants showed reduced duodenal bile acid concentrations (2.07 ± 1.3 mM in 10-19
days old and 5.8 ± 2.7 mM in 20-34 days old), compared to normal term infants (6.8 ± 2.7 mM in
three weeks to 8 months of age) (Lavy et al., 1971). Unlike adults, lower concentrations of bile acids
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in the duodenal content were observed in newborn infants during or within two hours after feeding
and this is likely due to the dilution of gastric content (Norman et al., 1972; Senger et al., 1986).
The synthesis of bile acids by the liver was reported to decrease due to aging in older life (Bertolotti
et al., 1993; Einarsson et al., 1985). (Einarsson et al., 1985) reported that the rate of bile acid
synthesis in adult healthy human volunteers (age 20 years) was ~1.74 mmol/day, while the
corresponding value in healthy elderly subjects (age 60 years) was only 0.91 mmol/day. Interestingly,
this reduction was compensated by a reciprocal increase in cholesterol secretion from ~53 umol/h to
~73 umol/h in the same age group. Khalil et al., (1985) reported that the sensitivity of the
gallbladder to plasma concentration of cholecystokinin (CCK) decreases with aging. This might be
compensated by an increased release of CCK, which, in turn, could increase the circulatory
concentration of CCK in the elderly. No effect of aging on gallbladder contractility and emptying
kinetic was found (Khalil et al., 1985). Very limited work has been done in determining the bile acid
concentration in human intestinal fluids in the older population. Annaert et al., (2010) found that
there was no statistically significant change in the concentrations of 11 individual bile salts in older
age compared to young adults. However, large inter-individual variation was observed in the
intraluminal bile salt concentrations which may partly contribute to the absence of significant
difference.
It is well known that the presence of bile salts increases the dissolution rate of poorly water soluble
drugs (Dressman et al., 1998; Jantratid et al., 2008; Persson et al., 2005). This could account for an
increase in absorption and bioavailability of these compounds after a meal compared to the fasted
state (Charman et al., 1997; Fleisher et al., 1999; Jones et al., 2006). There are limited data available
on the luminal bile salt content in children and older adults. No conclusions, therefore, can be drawn
on whether changes in bile salt concentrations and/or compositions in the young and aged
populations could affect drug solubility, dissolution and in turn bioavailability. Annaert et al., (2010)
reported that in general drug solubility was not significantly different in the aspirated intestinal
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fluids of older adults (62-72 years old) compared to young volunteers (18-25 years old). Again, large
inter-individual variability in drug solubility was observed.
2.1.5 Osmolality
The information on osmolality and surface tension of human gastrointestinal fluids from different
age groups is also limited. Wakayama et al. (1988) found a higher fasting gastric osmolality (253
mOsm/L) in infants (mean age of approximately 8 months) undergoing inguinal hernia repair in a
study by Lindhal et al., (1997) in adults (191 ± 36 mOsm/L). Billeaud et al. (1982) reported a
significant positive linear correlation between the osmolality of the diet and the osmolality in the
stomach and duodenum among 15 low birth weight neonates during the 3 hours after feeding. In
one study, osmolality of small intestinal aspirates from 62-72 years old (215 ± 37 mOsm.Kg-1) and 18-
25 years old (226 ± 35 mOsm.Kg1) human subjects (Annaert et al., 2010) were not significantly
different to one other.
The solubility of drug substances in the gut lumen is dependent on the interplay of a range of
physiological factors, the luminal fluid volume, pH, buffer capacity, ionic composition, bile salt,
viscosity and surface tension; however, there is limited data available on age-mediated changes
regarding drug solubility in the human gut. In a recent study, Maharaj et al., (2016) have developed
paediatric biorelevant media (i.e. P-FaSSGF, P-FeSSGF, P-FaSSIF and P-FeSSIF) reflective of age-
related changes in neonates and infants based on available literature values. The solubility of seven
BCS class-II compounds were compared in paediatric and adult biorelevant media and significant
differences were found in some cases. For example, the solubilities of fenofibrate and
carbamazepine in paediatric fasted-state gastric media (P-FaSSGF) were significantly different and
outside the 80-125% bioequivalent criterion compared to that in adult-based media. In one study
(Annaert et al., 2010), the average solubility of danazol (another neutral steroid) was found to be ~2
fold higher in intestinal aspirates from elderly humans (62-72 y, n=7) than in young subjects (18-25 y,
n=8), though this increase did not achieve statistical significance. It has also been reported that the
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solubility of an ionisable drug such as mesalamine in human gastrointestinal fluids is strongly
influenced by the fluid pH and its buffer capacity (Fadda et al., 2010), and as such the solubility of
such compounds is likely to be influenced by age-mediated differences in pH and the buffer capacity
of gastrointestinal fluids.
2.2 Changes in the gastrointestinal mucosa
The appearance of the small bowel mucosa, in terms of villous morphology, was reported to show
slight difference between young (mean age 43 years, range 13 to 59 years) and older (mean age 80
years, range 67 to 90 years) adults (Webster and Leeming, 1975). The study reported that leaf-
shaped villi were more commonly seen in the older group than in younger subjects. The mean value
of villous height for the older group was significantly smaller (371 µm) than weighted mean values
(471 µm) from pooled results of previous publications in young subjects. However, Corazza et al.,
(1986) reported that there is no significant difference in the surface to volume ratio of the jejunal
mucosa and the enterocyte height between young (mean age 36.8 years, range 15 to 60 years) and
older (mean age 71.5 years, range 65 to 82 years) subjects.
2.2.1 Gut associated lymphoid tissue (GALT)
In the human small intestine, the Peyer’s patches increase in size and number from early foetal life
to puberty, with a general tendency to decrease in number rapidly after puberty, plateauing
somewhat thereafter (Figure 2). They are well developed by the end of the fourth and the beginning
of the fifth month of gestation, and the relative distribution of Peyer's patches in the duodenum,
jejunum, and ileum was similar to that in older children (Cornes, 1965a).
The reduction in the number of patches with older age (70 and 95 years of age) was also gradual and
fairly equal throughout the length of the small intestine, though with age, a gradual loss of lymphoid
follicles within the patches was observed, and in some cases resulted in the appearance of
‘fragmented’ patches. In the latter case, this was seen to lead to the replacement of large patches by
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a ‘collection’ of small ones; well-developed by the end of the fourth and the beginning of the fifth
month of gestation. These patches were not seen to dissipate entirely in the oldest patient (95 year
old female) studied where 59 patches were still clearly visible in the small intestine of the oldest
patient (Cornes, 1965a, b).
Cornes (1965a, b) reported an increase in the number of Peyer’s patches in babies during gestation
to birth and a continual increase until puberty (15 years) (Figure 2, 3A). When the data reported by
Cornes (1965a, b) was dissected in different age groups and reanalyzed using Microsoft Excel, the
number of Peyer’s patches in the small intestine was found to decrease on further ageing, i.e., from
15 years to 95 years (Figure 4A). Where data was normalized to the number of patches per
centimetre length of the small intestine, there was no difference in the number of patches present
up to 15 years of age (Figure 3B), though a downward trend was still visible in individuals ranging
from 15 years to 95 years (Figure 4B). Interestingly, when data was normalized to the subject body
weights, an exponential decrease was observed with age until puberty (Figure 3C), which became
less significant on further ageing (adult to elderly, Figure 4C).
It was suggested that the average number of lymphoid follicles in the colon of the child is
comparatively greater than in adults, but there is otherwise no evidence of a decrease in the number
of lymphoid follicles in old age (Dukes and Bussey (1926). When the data was dissected in different
age groups and analysed using Microsoft Excel, a negative correlation was seen in the number of
lymphoid follicles per cm2 of the colon with age (Figure 5A). The average number of lymphoid
follicles per cm2 of the colon in younger subjects aged 15 years or less was 8.0 ± 2.3 (n=7), which
decreased to half in individuals aged between 16-40 years (4.0 ± 1.6 follicles/cm2, n=27). This
decreased further with age to 3.5 ± 1.6 (41-60 years, n=57) and 3.1 ± 1.6 (61-88 years, n=15). More
interestingly, when the data was grouped according to gender, it was found that the decrease in
average follicles did not appear in females, whereas a clear downward trend was apparent in male
subjects (Figure 5B).
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2.2.2 The mucus layer
It has been suggested that the protective mechanisms of the human gastrointestinal tract are
impaired with age (Newton et al., 2004), implicated by the higher statistical incidence of
gastrointestinal diseases in the elderly ranging from peptic ulceration to gastric cancer and
inflammatory bowel disease (Newton, 2004; Pullan et al., 1994). The normal gastro-duodenal
mucosal protection is the consequence of complex interplay between bicarbonate secretion and the
behaviour of the gastric mucus layer (Allen et al., 1993), to which end a decrease in bicarbonate
secretion by gastric (Feldman and Cryer, 1998) and duodenal (Kim et al., 1990) mucosa. An
increased production of mucus in the glands is stated as part of the development of the newborn GI
tract (Xu, 1996). During the perinatal period, the undernutrition results in decreased mucus levels in
the small intestine (Neu, 2007). For older people, reduced mucus thickness in the upper gut has
been reported, particularly in patients with H. pylori infection (Newton et al., 2000).
The age-mediated decrease in the number of mucus producing cells (Goblet cells) has also been
demonstrated in humans, which in turn results in a lower amount of secreted mucus over the
epithelium. Also, the total sialic acid concentration in human gastric aspirates was found to decrease
with age; suggesting a structural change in gastric mucus (Corfield et al., 1993). Here viewed on a
molecular level, it has been shown that mucosal concentrations of prostaglandins A and E – which
stimulate gastric mucus and bicarbonate secretion – are decreased in the elderly (Cryer et al., 1992a;
Cryer et al., 1992b), whilst bicarbonate secretion by gastric mucosa (Feldman and Cryer, 1998) and
duodenum (Kim et al., 1990) is also impaired in elderly subjects.
2.2.3 Mucosal enzymes and transporters
The intestinal epithelium accommodates a range of drug transporters (both influx and efflux) and a
family of membrane-bound metabolic enzymes. These enzymes and transporters contribute
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substantially to the absorption and bioavailability of a large numbers of drug substances. Limited
research has been conducted on the effect of age on the expression of solute carriers in the
intestine. Buddington et al. has reviewed ontogenetic development of intestinal nutrient
transporters in humans (Buddington and Diamond, 1989). However, the effect of this on drug
absorption is unclear.
The function of the efflux transporters is to expel compounds that have penetrated the intestinal
epithelium back into the gut lumen, with P-glycoprotein (P-gp) being the most studied amongst
them. P-gp is the product of the multidrug resistance gene MDR1 and is recognized as a member of
the APT-binding cassette super-family of membrane transport proteins (Hunter and Hirst, 1997).
Other efflux transporters include multidrug resistance-associated protein 2 (MRP2) and breast
cancer resistance protein (BCRP). The intestinal metabolic enzymes, known as cytochromes, are
responsible for the metabolism of variety of drug compounds, potentially decreasing their
bioavailability. The most important membrane-bound enzyme is the cytochrome P450 (CYP450),
with the most abundant form being CYP3A4 accounting for 80% of CYP enzymes in the small
intestine (Doherty and Charman, 2002; Suzuki and Sugiyama, 2000).
A clear expression of MDR1-mRNA can be observed in human fetal intestinal epithelium from 16 to
20 weeks fetal age (van Kalken et al., 1992). Fakoury et al. detected MDR1-mRNA in the intestine of
children aged 1 month to 17 years, however, they did not find a significant relation between P-gp
expression and age (Fakhoury et al., 2005). Miki et al. (2005) demonstrated that MDR1-mRNA
expression was 4-5 fold higher in the small intestine of young adults (15-38 years old) than in fetus
and neonates (0 years old). Again, they did not show a significant correlation between the
development and age. Mooij et al., (2014) found that intestinal transporter expression was
statistically significantly associated with age for MRP2, but not for MDR1.
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Miki et al., (2005) also reported a 4-fold higher mRNA expression of the CYP3A4 enzyme in the small
intestine of young adults than of fetus and neonates with no significant difference. However, in the
large intestine, the CYP3A4 mRNA expression was significantly higher (about 8-fold) in fetus than in
neonates and young adults. In contrast, the study by Fakoury et al., (2005) reported that the
duodenal mRNA expression of CYP3A4 was significantly higher in the first year of life and decreased
with age to lower values in older children (1-6 years and 6-17 years). In an earlier study Johnson et
al., (2001) demonstrated a developmental pattern of increasing CYP3A4 mRNA expression and
enzyme activity from fetus to children older than 12 years (Figure 6). However, a statistically
significant difference was only observed between neonates and children > 12 years.
Literature has provided limited evidence on the developmental effect on the activity of P-gp and
CYP3A4 in the intestine of children, let alone their impact on the absorption of drug molecules that
are substrates of these transporters and enzymes. de Wildt et al., (2002) have observed a nearly 10-
fold lower rate in midazolam clearance after oral administration in preterm infants compared to
adults. The oral midazolam clearance is dependent on the intestinal and hepatic CYP3A4 activities
(Thummel et al., 1996). The possible low level of CYP3A4 activity in the intestine of neonates could
explain this low clearance rate and a resultant higher oral bioavailability in pre-term infants (median
49%) compared to adults (24-38%) (de Wildt et al., 2002). Johnson et al. (2008) have suggested a list
of drugs used in children with variable oral bioavailability which is believed to be due in part to
intestinal first-pass metabolism (Johnson and Thomson, 2008).
The effect of older age on the intestinal CYP3A4 activity was unclear. Miki et al. demonstrated a
nearly one-third decrease in CYP3A4 mRN expression in the elderly (67-85 years) compared to young
adults (15-38 years); however, no significant correlation was found between age and the mRN
expression (Miki et al., 2005). Gorski et al. investigated relative susceptibility of intestinal and
hepatic CYP3A activity to induction by rifampin (a CYP3A inducer), measured by the clearance of
CYP3A substrate midazolam (Gorski et al., 2003). They reported a nearly one-third reduction in the
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oral clearance of midazolam in the elderly (age 70 ± 4 years men and 72 ± 5 years women, clearance
rate 19 ± 18) compared to young adults (age 27 ± 4 years men and 26 ± 4 years women, clearance
rate 36 ± 26), and again, no significant difference was detected. Fromm et al. studied the effect of
rifampicin induction to intestinal CYP3A4 activity on pre-hepatic clearance of S-verapamil after oral
administration in older adults (67.1 ± 1.2 years) (Fromm et al., 1998). Bioavailability of verapamil
decreased significantly from 14.2 ± 4.3% to 0.6 ± 0.5% as a consequence of the rifampicin induction.
However, this was not compared to the effect in younger adults. The impact of aging on the activity
and expression of P-gp has been investigated in a number of tissues in human, especially in
lymphocytes (Table 2). However, the effect on intestinal P-gp activity in human and its consequence
in drug absorption in older age remains largely unclear.
2.3 Changes in gastrointestinal transit and motility
The paediatric data for gastrointestinal transit and motility has been well reviewed focusing on its
impact on oral drug delivery design (Bowles et al, 2010). There are developmental oropharyngeal
anatomical differences, mainly from birth into early childhood. The oesophageal transit time is
comparable to normal younger adult values. The gastric emptying time of liquids is reported to reach
adult values by around 6-8 months of age (Bowles et al, 2010). The intestinal transit time is similar
between younger (2 months-3 year old) and older segments of paediatric population (3-12 year old)
(Bowles et al, 2010). The colonic transit time in children is also comparable to normal adult values
(Bowles et al, 2010).
The motor function of the gastrointestinal tract is relatively well preserved in healthy aged people
while diseases and concomitant medicine use may alter the gastrointestinal system function at
advanced age (Sinclair et al., 2012). In order to focus on the effect of the normal ageing process on
gastrointestinal transit and motility, the changes that may occur due to age-related diseases and
concomitant drug use are not mentioned in this paper. The age-related changes are significant in
oropharyngeal and oesophageal motility, in particular reduction in lower oesophageal sphincter
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pressure resulting in impairments including dysphagia and reflux (Grande et al., 1999; Grassi et al.,
2011). The oesophageal dysmotility is most common in the very old (Hollis and Castell, 1974). The
gag reflex is absent in 43% of elderly subjects (Davies et al., 1995).The oesophageal sphincteric and
peristaltic function deteriorates with ageing (Grande et al., 1999; Ren et al., 1993; Robbins et al.,
2006); changes in peristalsis are seen from as early as 40 years of age (Gregersen et al., 2008).
Nevertheless, the magnitude of amplitude of oesophageal pressure changes is modest (Orr and
Chen, 2002).
Although a modest slowing of gastric emptying time (Brogna et al., 1999; Evans et al., 1981; Kao et
al., 1994) is reported to be associated with advanced age, the effect of natural healthy ageing
process is reported to be minor on the GI motility (Fich et al., 1989; Husebye and Engedal, 1992;
Kagaya et al., 1997; O'Mahony et al., 2002; Russell, 1992). The fasting and fed gastric motility do not
differ between younger (18-39 year old) and older (40-69 year old) adults (Fich et al., 1989). An early
study (Haboubi et al., 1988) indicated that small intestinal transit was slowed in elderly subjects but
later studies using gamma camera (Madsen and Graff 2004) and video capsule endoscopy (Fischer
and Fadda, 2016) confirmed that transit remains unaffected by age (Figure 7). However the
influence of age on small intestinal transit time is still inconclusive and requires further investigation
on larger cohorts with well-defined age bands. Healthy ageing does not substantially affect the small
intestine motility in contrast to the altered colonic transit in elderly (Sinclair et al., 2012). In the
colon, there is evidence of a prolonged transit time due to a decline in propulsive activity in the
colon related to a reduction in both neurotransmitters and receptors (Britton and McLaughlin, 2013;
Gomes et al., 1997; Madsen and Graff, 2004; Salles, 2007). The age-related loss of enteric cholinergic
neurons is reported to be associated with the delay in colonic transit, leading to inefficient peristalsis
(Wiskur and Greenwood-Van Meerveld, 2010). Further studies are required to be conducted in order
to understand the true age-related changes in gut structured function by measuring gut function
against age-related normal values rather than against data from younger adults (O'Mahony et al.,
2002).
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2.4 Changes in the gastrointestinal microbiota
The human gut is intensively colonised by microbes. The numbers of microbes and the composition
of the microbiota vary significantly at different sites in the gastrointestinal tract (Ouwehand and
Vesterlund, 2003). The stomach contains relatively low numbers of bacteria (< 104 CFU/ml). In
comparison, a relatively higher density of bacteria colonise the small intestine, with approximately
103-105 CFU/ml in the duodenum and jejunum and 107-108 CFU/ml in the ileum respectively. The
colon is the main site of microbial colonisation, containing an estimated 1.5 kg of microbes
equivalent to approximately 1014 microbes (1010-1011 CFU/ml) (Moore and Holdeman, 1974;
Ouwehand and Vesterlund, 2003).
The intestines of new-born infants are considered to be sterile. Intestinal bacteria start to colonise
within hours and a rapid increase in bacterial count occurs within the first few days. At the end of
the first week, infant faecal bacteria reach a level of 109-1010 CFU/g of wet faeces (Palmer et al.,
2007). However, infant intestinal microbiota is very different from that found in adults with low
diversity and low complexity (Adlerberth and Wold, 2009). The neonatal gut presents high level of
oxygen which prevents the growth of anaerobes. Therefore, enterobacteria dominate the early life
flora including E. coli and enterococci (Adlerberth and Wold, 2009). During the first week of life,
luminal anaerobic bacterial populations expand. These bacteria species consume the oxygen and
create an anaerobic environment in the gut, which further favours the growth of anaerobic bacteria
such as Bifidobacterium.
In the first months of life, the microbiota of the infant gut varies remarkably between individuals.
The composition of the intestinal microbiota in early infancy is affected by many factors such as the
mode of delivery, type of infant feeding, hospitalisation after birth and use of antibiotic (Penders et
al., 2006). This inter-individual diversity decreases in the early months and the gut flora progresses
toward an adult-like profile by the end of the first year. A Danish study reported significant changes
in intestinal microbiota in infants before 18 months of life (Bergstrom et al., 2014). The intestinal
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microbiota does not completely reach the adult state until much later in childhood; differences in
viable counts of predominant bacterial species could still be seen between children up to 7 years old
and adults (Hopkins et al., 2002; Ringel-Kulka et al., 2013).
In the older population, mean total anaerobe counts remain similar to that of young adults;
however, shifts in dominant bacteria species are frequently reported (Woodmansey, 2007). One of
the most marked changes in older people is the decline in numbers of bifidobacteria (Hopkins et al.,
2002; Mitsuoka, 1992; Mitsuoka et al., 1974; Woodmansey et al., 2004). It was reported that the
species diversity of bifidobacteria is also reduced in the elderly, with dominant species being
Bifidobacterium adolescentis, Bifidobacterium angulatum and Bifidobacterium longum (He et al.,
2001; Mitsuoka, 1992; Mitsuoka et al., 1974; Woodmansey et al., 2004). Studies have shown that
total numbers and species diversity of bacteroides also decrease in older age (Claesson et al., 2011;
Guigoz et al., 2002; Hopkins et al., 2002; Woodmansey et al., 2004). Bacteroides species contribute
to the digestion of majority of polysaccharides to short-chain fatty acids in the colon. Reductions in
amylolytic activities and overall fecal excretion of short-chain fatty acids have been reported in the
older population (Woodmansey et al., 2004). This could be the consequences of the decline in
bacteroides species in the colon. In contrast, numbers of facultative bacteria species were found to
increase in the aged gut (Bouhnik et al., 2007; Guigoz et al., 2002; Hopkins et al., 2001; Woodmansey
et al., 2004). In particularly, higher numbers of enterobacteria, streptococci, staphylococci and
yeasts were reported in the elderly compared to young adults (Woodmansey et al., 2004).
A cross-sectional study examined fecal microbiota in older populations in four European countries,
France, Germany, Italy and Sweden (Mueller et al., 2006). It was found that age effects in intestinal
microbiota composition were dependent on the geographical location of the subjects. For example,
higher levels of eubacteria were detected in the elderly compared to young adults in Germany;
whereas a decrease in levels of these species with age was found in Italy. The older subjects in
Sweden had the highest levels of Fecalibacterium prausnitzii in all study countries. However, higher
22
proportions of bifidobacteria were found in Italian subjects than in subjects from any other countries
and this effect was independent of age. Another study suggested that many external factors affect
the intestinal microbiota composition in the elderly. Significant correlations were found between
microbiota composition in the elderly and health factors including diet, frailty, co-morbidity,
nutritional status and markers of inflammation (Claesson et al., 2012). It was reported that older
individuals with high frailty scores had a significant reduction in the number of lactobacilli compared
to healthy older adults; whereas significantly higher levels of Enterobacteriaceae was found in these
very frail older subjects (van Tongeren et al., 2005). Table 3 summarizes the faecal microbiota
composition of children, adults and the elderly in selected studies.
Bacteria present in the gut lumen are capable of metabolizing a range of drug substances (Sousa et
al., 2008), affecting their bioavailability in modified release formulations. Drug delivery systems
targeting to the colon are designed to utilize bacteria activity for the release of active substances.
These include the inclusion of polysaccharides that are substrates to colonic bacteria metabolism
and pro-drugs, such as the prodrugs of 5-aminosalicylic acid (mesalazine), including sulfasalazine,
balsalazide, and olsalazine, for the treatment of ulcerative colitis. These prodrugs are poorly
absorbed in the stomach and small intestine and rely on colonic anaerobic bacteria to cleave the azo
linkage and liberate the active drug (Sousa et al., 2014). Changes in colonic microbiota, be it an
increase or reduction in number, species and/or activity, in children and older adults might affect the
absorption of drug compounds that either benefit from or be destroyed by these microorganisms.
3. Conclusion and future perspectives
Age is an important determinant that impacts on the absorption and metabolism of drugs. It is
apparent from this paper that many physiological and functional aspects of the human gut differ in
children and older individuals from young adults. However, there are many knowledge gaps on age-
related changes in the gut. The heterogeneity of both age groups further complicates the situation,
as children do not develop at the same rate nor do the elderly age uniformly. Considering the
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rareness of healthy older patients, individual studies should be conducted on the geriatric
population with co-morbidities and multiple medications, to consider the potential influence of
concomitant diseases on the in-vivo fate of the drug in the gastrointestinal tract. Equally, further
understanding on the chronological age-related changes (only healthy young and healthy older age-
related) in the gut is important. In the case of the elderly, frailty should be a better indicator for the
aged-gut compared to chronological age as the ageing status should be ideally defined by connecting
the decline in physiological capacity and increased risk of vulnerability to disease.
Children and older patients are often underrepresented in clinical trials resulting in a lack of
evidence based information on the effect of ageing on oral drug bioavailability. Although it is known
that the function of GI tract is altered during developmental stages or with advanced age, the effects
on pharmacokinetics and/or pharmacodynamics of the orally administered drug are often unclear.
This data obtained from children and older subjects is essential as the prediction of clinical outcomes
based on the gut physiological changes and/or extrapolation from healthy young adults may not be
appropriate. The impact of prediction tools (e.g. physiologically-based
pharmacokinetic/pharmacodynamics modelling and simulation) should be further explored to
inform clinical trials in younger and older populations. Age related changes in barriers to drug
delivery should be available to formulation scientists and adequately reflected in the design of
personalized formulations to ensure the development of high quality, safe and effective drug
therapies for use in young and older patients.
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List of Figures
Figure 1. Postprandial time to return to pH 5, 4, 3 and 2 in elderly (65-83 years, n=79) and young (21-35 years, n=24)
subjects. Figure plotted using data from (Russell et al., 1993).
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Figure 2. Effect of age on the number of Peyer’s patches in human small intestine. B: before term (from 24 to 37 weeks
gestation), A: after term (from birth to 95 years). Figure reproduced from (Cornes, 1965b).
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Figure 3. Effect of age on the number of Peyer’s patches in human small intestine in subjects up to 14 years of age. Figure
plotted using data from (Cornes, 1965b).
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Figure 4. Effect of age on the number of Peyer’s patches in human small intestine in subjects from 15 to 95 years of age.
Figure plotted using data from (Cornes, 1965b).
28
Figure 5. Effect of age on the number of lymphoid follicles per cm2 of human colon. Figure drawn using data from (Dukes
and Bussey, 1926).
29
Figure 6. (a) Age related changes in the villi corrected expression of CYP3A4 in histologically normal duodenal sections. The
numbers in each group are given in brackets and error bars are ± s.d. Statistical significance differences (P < 0.05) were
achieved between foetus and all other groups and between neonate and children > 5 years. (b) Age related changes in
villin corrected CYP3A4 activity measured by the rate of 6OHT formation in histologically normal duodenal sections. The
numbers in each group are given in brackets and error bars are ± s.d. A statistically significant difference (P < 0.05) was
observed only between neonates and children > 12 years. (Reproduced from (Johnson et al., 2001).
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Figure 7. Effect of age on small intestinal transit time , figure adapted from [A] Madsen and Graff (2004) and [B] Fischer
and Fadda (2016)
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List of Tables
Table 1. Effects of ageing on the human gastrointestinal environment.
GI characteristics Mean ± SD
Young Adult Elderly
pH 8-14 y (n=12)[1] 18-65 y (n=39)[2] 65-83 y (n=79)[3]
Stomach 1.6 1.5 1.1-1.6
Small intestine (SI)
Duodenum 6.5 6.4 6.5
Jejunum 6.6 6.6
Mid SI 7.0 7.0
Distal SI 7.4 7.3
Caecum 5.9 5.7
Colon
Ascending 5.6 5.6
Transverse 5.5 5.7
Descending 6.0 6.6
Rectosigmoid 6.5 6.6
Faeces 6.4 6.5 6.57[4]
Buffer Capacity (mmol/L/ΔpH) 
Stomach 14 (20-32 y)[5]
Small intestine (SI)
Duodenum 18-30 (20-32 y)[5]
Jejunum 3.2 ± 1.3 [6]
Ileum 6.4 [6]
Caecum -
Colon
Ascending 18.9 (20-30 y) [7]
Transverse
Descending
Rectosigmoid
Faeces
Bile salts (mM), Duodemum
Fasted 1.6-5.9[10-16]
Fed 1.7 (under 2 days )[19] ~ 10[10-13, 17,18]
3.3 (2-7 days)[19]
8.5 (10 days to 7 mo)[19]
Osmolality (mOsm.Kg-1) 226 ± 35 (18-25 y)ref 215 ± 37 (62-72 y)ref
Gut associated lymphoid tissue (GALT)
SI (Peyer’s patches) [8] 222 ± 91 (0-14 y) 273 ± 67 (15-38 y) 181 ± 43 (41-95 y)
Colon (follicles/cm2) [9] 8.0 ± 2.3 (≤15 y) 4.0 ± 1.6 (16-40 y) 3.5 ± 1.6 (41-60 y)
3.1 ± 1.6 (61-88 y)
[1] Fallingborg et al 1990, [2] Fallingborg et al 1989, [3] Russell et al 1993, [4] Bouhnik et al 2007, [5] Kalantzi et al., 2006, [6] Fadda et al
2010, [7] Diakidou et al., 2009, [8] Cornes 1965ab, [9] Dukes and Bussey 1926, [10] (Armand et al., 1996), [11] (Clarysse et al., 2009),
[12](Persson et al., 2005), [13] (Dressman et al., 1998), [14] (Lindahl et al., 1997), [15] (de la Cruz Moreno et al., 2006), [16] (Deferme et al.,
2003), [17] (Fausa, 1974), [18] (Kalantzi et al., 2006), [19] (Challacombe et al., 1975)
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Table 2. Studies on the effect of aging on P-gp activity and expression in human.
Parameter tested Cell type Effects of aging Reference
P-gp activity B and T lymphocytes ↓ (Pilarski et al., 1995)
P-gp expression T lymphocytes ↑ (Aggarwal et al., 1997)
P-gp activiety ↑
ABCB1 expression ↑
P-gp expression Enterocytes → (Lown et al., 1997)
P-gp activity B and T lymphocytes → or ↓ (Machado et al., 2003)
P-gp activity Bone marrow stem cells → or ↑ (Calado et al., 2003)
P-gp activity Natural killer cells → (Brenner and Klotz,
2004)
P-gp activity Blood-brain barrier ↓ (Toornvliet et al., 2006)
ABCB1 expression Liver → (Prasad et al., 2014)
P-gp activity Blood-brain barrier ↓ in male, → in female (van Assema et al.,
2012)
P-gp activity Intestine → (Larsen et al., 2007)
P-gp expression Male lymphocytes ↑ (Vilas-Boas et al., 2011)
P-gp activity →
* Studies published prior to 2007 were adapted from (Mangoni, 2007). Increase (↑); decrease (↓); no change (→)
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Table 3. Selected studies on the composition of the faecal microbiota in children, adults and the elderly*
Study
population
Age Total
anaerobes
Bacteroides Bifidobacterium Enterobactria Enterococci Clostridia Lactobacilli Reference
Children 1 w 4.8 - 9.3 6.2 - 10.2 6.2 - 9.4 5.7 - 9.0 3.1 - 7.2 4.4 - 7.0 (Adlerberth and Wold, 2009)†
5 w 6.0 - 10.1 4.3 - 11.3 6.1 - 9.6 4.5 - 9.6 3.0 - 8.1 5.0 - 9.1 (Adlerberth and Wold, 2009)†
1 m 9.40 (5.74-
10.36)
10.71 (6.84-11.56) 5.24 (2.70-
9.57)
8.70 (7.92-
10.73)
(Scheepers et al., 2015)
16 m - 7 y 10.4 ± 0.2 9.9 ± 0.4 9.8 ± 0.3 8.0 ± 0.4 5.5 ± 0.5 7.2 ±0.8 6.6 ± 0.7 (Hopkins et al., 2002)
Adults 21 - 34 y 10.5 ± 0.1 10.0 ± 0.1 9.1 ± 0.2 5.9 ± 0.5 6.1 ± 0.7 6.6 ± 0.4 6.7 ± 0.6 (Hopkins et al., 2002)
19 - 35 y 9.9 ± 0.1 9.5 ± 0.2 5.8 ± 0.6 6.5 ± 0.9 5.6 ± 1.0 6.3 ± 1.0 (Woodmansey et al., 2004)
21 - 39 y 9.11 9.42 9.54 (Tiihonen et al., 2008)
Elderly 67 - 88 y 10.1 ± 0.2 9.6 ± 0.2 7.3 ± 1.0 6.7 ± 0.8 6.0 ± 0.8 6.9 ± 0.6 5.4 ± 1.0 (Hopkins et al., 2002)
67 - 75 y 6.5 ± 2.1 8.1 ± 1.6 7.3 ± 0.4 5.3 ± 1,7 4.1 ± 1.8 (Woodmansey et al., 2004)
> 62 y 10.3 ± 0.5 8.6 ± 1.0 6.0 ± 1.4 (Bartosch et al., 2005)
69 ± 2 y 10.09 ± 0.07 8.5 ± 0.26 7.69 ± 0.21 3.25 ± 0.25 (Bouhnik et al., 2007)
77 - 97 y 8.8 6.0 7.7 6.1 3.5 5.1 (Guigoz et al., 2002)
68 - 84 y 9.29 9.59 9.59 (Tiihonen et al., 2008)
*Amounts are given as log10 number of bacteria/g fresh faecal weight, †Adapted from reference (Adlerberth and Wold, 2009), summarising studies on intestinal microbiota in children
performed until 1990.
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